Matinas BioPharma Holdings, Inc. announces positive results from an additional in vivo study in healthy mice with an oral LNC formulation of docetaxel, a well-established chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors. Docetaxel is currently only administered intravenously and is frequently associated with significant side effects and treatment-limiting toxicities. The goal of this study was to determine whether an oral LNC formulation of docetaxel could improve the overall safety profile of conventional IV-administered docetaxel.

The study included healthy BALB/c mice (n=24) divided into three treatment groups: Control animals treated with oral saline. IV-docetaxel (30 mg/kg, or 0.6 mg/dose) administered once a week for three weeks. IV-docetaxel (30 mg/kg, or 0.6 mg/dose) administered once a week for three weeks.

Oral LNC-docetaxel (37.5 mg/kg, or 0.75 mg/dose) administered once daily over three weeks. The primary endpoint was change in body weight over the treatment period.